Stanford's Virtual Biotech runs 37,075 parallel AI-agent tasks to simulate drug R&D, published in Science
jiqizhixin · x · 2026-09-25
Stanford University published Virtual Biotech in Science: a multi-agent AI system that simulates an entire biotech R&D organization. A virtual chief scientific officer sits at the top, coordinating agents for target discovery, safety assessment, treatment selection, and clinical development, running 37,075 task instances in parallel.
The system targets the long-standing problem of target validation, which requires integrating human genetics, functional genomics, and clinical evidence scattered across databases and specialist teams. Rather than a real company, it's a scalable simulation of an AI-organized R&D pipeline, illustrating a new organizational paradigm for AI in drug discovery.
More from Research
- DeepMind launches AlphaGenome 2, spotting nearly 2x more gene-regulating mutations — GoogleDeepMind · 2026-11-11
- Active learning with weak supervision cuts surgical video annotation effort by ~50% — Laparoscopes · 2026-11-11
- Tuva Labs takes 1st on ARC-AGI-2, 2nd on ARC-AGI-3 in ARC Prize 2026 — GregKamradt · 2026-11-11
- Sakana AI × Pathway Post-Transformers lecture on AI and the brain now online — kaixhin · 2026-11-11
- Defending METR: public data can't second-guess its AI speedup findings — peterwildeford · 2026-11-11
- Adversarial RL envs for backdoor insertion vs. detection: where does it converge? — DimitrisPapail · 2026-11-11